TD Cowen Maintains Buy on Evolent Health, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Neutral 68.3%

Neg 0% Neu 68.3% Pos 0%

TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $8 to $5.